)
)
)
Securing the Value of Life Science Acquisitions: Navigating Foreign Investment Screening and National Security Risk
High-value life science acquisitions seldom occur without scrutiny. As governments increasingly treat advanced biotechnology, pharmaceutical manufacturing capabilities, critical medicines, health data and proprietary research platforms as strategically sensitive assets, cross-border transactions can trigger foreign investment screening and national security review across multiple jurisdictions.
This session will examine how legal teams can safeguard the value of life science acquisitions by navigating foreign investment clearance processes and anticipating regulatory scrutiny. Bringing together general counsel and private practice perspectives, the discussion will explore how companies can identify filing obligations early, manage parallel reviews and navigate the clearance process without jeopardising deal timelines or outcomes.
- When do life science acquisitions trigger foreign investment screening, and which transactions are most likely to attract scrutiny?
- How do regulators assess the sensitivity of life science assets when reviewing foreign investment?
- How can legal teams factor foreign investment risk into transaction structure and deal timelines?
- How should companies navigate parallel foreign investment reviews across multiple jurisdictions?
- What conditions or mitigation measures can authorities impose, and how can legal teams manage their impact on the transaction and post-closing operations?
